ology has contributed importantly to the rise of cardiovascular medicine. 2 With the advent of drug-eluting stents, restenosis has become less important, 3 but whether or not it affects hard outcomes including mortality, or represents a clinical nuisance only is still a matter of debate. Whether we really use percutaneous coronary interventions (PCIs) only in those patients who truly need it has also been questioned by many critics of current clinical practice. 4 Finally, although primary PCI has become the standard of care in acute coronary syndromes (ACS), the event rate in the years thereafter remains high, particularly due to the development of systolic dysfunction and heart failure. Thus, the possibility of improving current ACS management further, for instance by limiting reperfusion injury (thereby protecting the myocardium), is another open question. Almost all pharmacological interventions have failed, although pre-conditioning appears to be promising. 5 Grüntzig started in coronary circulation, but structural interventions have recently become almost as important. Catheter-based interventions for aortic stenosis or mitral regurgitation have successfully been introduced in selected patients. 6 In contrast, percutaneous closure of a patent foramen ovale (PFO) in patients with cryptogenic stroke is an effective procedure and is very controversial. All these open issues of interventional cardiology are addressed in the current issue of the European Heart Journal. of onset of pain undergoing PCI for STEMI. The primary endpoint was infarct size expressed as area under the curve (AUC) for creatine kinase (CK) and troponin I (TnI) over 3 days. Secondary endpoints measures were infarct size assessed by cardiac magnetic resonance (CMR) and safety outcomes. Infarct size was not significantly different between groups. There were no significant differences in CMRassessed myocardial salvage index or left ventricular ejection fraction or in the mean 30-day echocardiographic ejection fraction either. Surprisingly, a greater number of adjudicated safety events occurred in the TRO40303 group. Thus, inhibition of mitochondrial permeability transition by TRO 40303 in STEMI patients treated with PCI did not reduce reperfusion injury of the ischaemic myocardium. The fourth paper on 'Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis' by Peter Jüni et al.
14 from the Institute of Social and Preventive Medicine in Berne Switzerland accompanied by an Editorial by Khalid Benkhadra from Mayo Clinic, Rochester, MN, USA 15 uses novel and complex statistics to investigate a possible role for a PFO as a cause of paradoxical embolism and cryptogenic stroke. As the randomized trials have failed to demonstrate superiority of PFO closure over medical therapy, possibly due to lack of power and many crossovers, Jüni and colleagues performed a network meta-analysis of published trials. They included four randomized trials with 2963 patients and 9309 patient-years using Amplatzer (AMP), STARFlex (STF), and HELEX (HLX) closure devices. Patients allocated to PFO closure with AMP were less likely to experience a stroke than patients allocated to medical therapy [rate ratio (RR) 0.39], while no effect was found for STF (RR 1.01) and HLX (RR 0.71). The probability to be best in preventing strokes was 77.1% for AMP, 20.9% for HLX, 1.7% for STF, and 0.4% for medical therapy. No significant differences were found for transient ischaemic attack and death. The risk of new-onset atrial fibrillation was more pronounced for STF (RR 7.67) than for AMP (RR 2.14) or HLX (RR 1.33). Thus, it appears that the effectiveness of PFO closure depends on the device used as only the AMP was superior to medical therapy in preventing strokes in patients with cryptogenic embolism.
